DelveInsight Report Details Pipeline for Head and Neck Cancer Treatments

Market research firm DelveInsight has published a report detailing the development landscape for treatments targeting recurrent or metastatic head and neck cancer (HNC). The "Recurrent or Metastatic Head and Neck cancer - Pipeline Insight, 2026" report analyzes the pipelines of more than 40 companies worldwide, encompassing over 40 drug candidates.

Head and neck cancers represent the sixth most common cancer globally. Patients with recurrent or metastatic disease historically face a poor prognosis, often receiving palliative care. Despite the approval of cetuximab in 2006, no new targeted therapies have been approved for HNSCC, the most common histology, highlighting significant knowledge gaps and a lack of predictive biomarkers.

Research is focused on novel therapeutic approaches. Notably, Merck's Xevinapant, an inhibitor of apoptosis proteins (IAP), has received FDA Breakthrough Therapy Designation for previously untreated, locally advanced squamous cell carcinoma of the head and neck. Sichuan Baili Pharmaceutical is developing SI-B001, a bispecific antibody targeting EGFR and HER3.

The report provides comprehensive insights into drug candidates across various stages of development, including mechanisms of action, clinical trial data, and commercial assessments. Key players are actively engaged, with some candidates, such as a product from Eisai Co., reaching Phase III clinical trials.